NCT05500989 PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
| NCT ID | NCT05500989 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Maastricht University Medical Center |
| Condition | Pre-Eclampsia |
| Study Type | OBSERVATIONAL |
| Enrollment | 226 participants |
| Start Date | 2016-11 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 226 participants in total. It began in 2016-11 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pregnancy is considered a cardiovascular (CV) stress test, and complicated pregnancies are associated with an increased risk for cardiovascular disease (CVD) later in life. Moreover, it is known that often the pregnancy induced CV adaptation does not resolve completely after a short postpartum (PP) period and it is not clear whether these induced changes will resolve over a longer period of time (i.e. in the upcoming months/years after delivery). Understanding the cardiac adaptation during pregnancy and the reversal process in the postpartum period, as well as the factors that influence this these processes, may provide us not only insight in this mechanism, but may help us in identifying factors that may be target points for modification.
Eligibility Criteria
Inclusion Criteria: * Women aged ≥ 18 years * Controls: Women with an uncomplicated pregnancy at the moment of inclusion (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies) * Cases: Women diagnosed with a preeclamptic pregnancy at the moment of inclusion Exclusion Criteria: • Women who do not want to be informed about the results of the tests, or women who do not want their general practitioner and specialist(s) to be informed about the test results * Allergy or intolerance to glyceryl trinitrate, betablockers or iodinated contrast media. * Controls: Pre-existing chronic hypertension treated with antihypertensive medication or autoimmune disorder.
Contact & Investigator
Marc Spaanderman, MD, PhD
PRINCIPAL INVESTIGATOR
Maastricht University Medical Center
Frequently Asked Questions
Who can join the NCT05500989 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Pre-Eclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05500989 currently recruiting?
Yes, NCT05500989 is actively recruiting participants. Contact the research team at gwyneth.jansen@mumc.nl for enrollment information.
Where is the NCT05500989 trial being conducted?
This trial is being conducted at Maastricht, Netherlands.
Who is sponsoring the NCT05500989 clinical trial?
NCT05500989 is sponsored by Maastricht University Medical Center. The principal investigator is Marc Spaanderman, MD, PhD at Maastricht University Medical Center. The trial plans to enroll 226 participants.